Research programme: osteoporosis therapeutics - Chipscreen
Alternative Names: CS 0038Latest Information Update: 15 Aug 2007
Price :
$50 *
At a glance
- Originator Chipscreen Biosciences
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 21 Jul 2004 Preclinical trials in Osteoporosis in China (unspecified route)